Background
Many patients with heart failure (
HF
) with reduced ejection fraction (
HF
r
EF
) experience improvement or recovery of left ventricular ejection fraction (
LVEF
). Data on clinical characteristics, outcomes, and medical therapy in patients with HF with improved ejection fraction (HFiEF) are scarce.
Methods and Results
Of 5625 consecutive patients hospitalized for acute
HF
in the KorAHF (Registry [Prospective Cohort] for Heart Failure in Korea) study, 5103 patients had baseline echocardiography and 2302 patients had follow‐up echocardiography at 12 months.
HF
phenotypes were defined as persistent
HF
r
EF
(
LVEF
≤40% at baseline and at 1‐year follow‐up),
HF
i
EF
(
LVEF
≤40% at baseline and improved up to 40% at 1‐year follow‐up),
HF
with midrange ejection fraction (LVEF between 40% and <50%), and
HF
with preserved ejection fraction (
LVEF
≥50%). The primary outcome was 4‐year all‐cause mortality from the time of
HF
i
EF
diagnosis. Among 1509
HF
r
EF
patients who had echocardiography 1 year after index hospitalization, 720 (31.3%) were diagnosed as having
HF
i
EF
. Younger age, female sex, de novo
HF
, hypertension, atrial fibrillation, and β‐blocker use were positive predictors and diabetes mellitus and ischemic heart disease were negative predictors of
HF
i
EF
. During 4‐year follow‐up, patients with
HF
i
EF
showed lower mortality than those with persistent
HF
r
EF
in univariate, multivariate, and propensity‐score–matched analyses. β‐Blockers, but not renin–angiotensin system inhibitors or mineralocorticoid receptor antagonists, were associated with a reduced all‐cause mortality risk (hazard ratio: 0.59; 95%
CI
, 0.40–0.87;
P
=0.007). Benefits for outcome seemed similar among patients receiving low‐ or high‐dose β‐blockers (log‐rank,
P
=0.304).
Conclusions
HF
i
EF
is a distinct
HF
phenotype with better clinical outcomes than other phenotypes. The use of β‐blockers may be beneficial for these patients.
Clinical Trial Registration
URL
:
https://www.clinicaltrials.gov
. U...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.